Search
site map
IP Handbook Blog
Your source for expert commentary on IP management issues.
Go to the blog
About
MIHR
PIPRA
Fiocruz, Brazil
bioDevelopments- Institute
|
NUGENT, Rachel
Rachel is a senior associate in CGD’s Global Health Programs. She provides economic and policy expertise to support HPRN Working Groups, manages CGD programs on Population and Economic Development, and conducts research on other global health topics. She has 25 years of experience as a development economist, managing and carrying out research and policy analysis in the fields of health, agriculture, and the environment. Prior to joining CGD, Rachel worked at the Population Reference Bureau, the Fogarty International Center of the U.S. National Institutes of Health, and the United Nations Food and Agriculture Organization.
She received her Ph.D. in Economics from George Washington University, and served as associate professor and chair of the economics department at Pacific Lutheran University in Tacoma, Washington. Rachel’s publications include a range of topics, from the cost-effectiveness of noncommunicable disease interventions and health impacts of fiscal policies, to impacts of microcredit on the environment in developing countries and the economic impacts of transboundary diseases and pests.
Abstract
Global Health: Lessons from Bayh-Dole
Abstract:
Public sector institutions help deliver public health goods. By extension, universities that receive public research funds must deliver a benefit to the public that goes beyond licensing a discovery to the private sector for development. In the United States, 25 years of experience with the Bayh-Dole Act, which governs the use of intellectual property (IP) derived from public research, offers both lessons and warnings for developing countries currently establishing their own IP systems. Bayh-Dole successfully created a large body of IP from publicly funded research. Absent a strong profit motive for the private sector, however, the Act has been much less successful at producing public goods for health. Current practice undervalues the “public benefit” aspect of the mandate, especially for the poor. Possible ways to address this mandate would be for public sector entities (and their academic partners in the biomedical sciences) to invest some of their earnings from licensing publicly funded discoveries into programs for neglected diseases of the poor. IP rights from public funded research could also be leveraged in negotiating licensing agreements with the private sector to address these neglected diseases. IP laws and institutions should be designed to encourage such sharing. The public and academic research sectors should also seek a new compact with the private sector aimed at reducing the burden of disease affecting the poor.
|